Fast knee pain trial recruitment boosts Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals (ASX: PAR) has fully recruited trial participants for its phase 2b clinical trial for knee osteoarthritis, leaving it on track to report trial results before the end of this year. Paradigm chief executive, Mr Paul Rennie, said the fast recruitment showed the strong demand for a new “breakthrough’’ treatment for the treatment of … Continue reading Fast knee pain trial recruitment boosts Paradigm Biopharmaceuticals